Literature DB >> 26593241

Designing Irreversible Inhibitors--Worth the Effort?

Concepción González-Bello1.   

Abstract

Despite the unquestionable success of numerous irreversible drugs that are currently in clinical use, such as acetylsalicylic acid (Aspirin) and penicillin, the number of such approved drugs is much lower than that of noncovalent drugs. Over the years, the potential off-target effects of these types of compounds have been the primary concern that has hampered their development. However, their remarkable advantages over noncovalent drugs and a better analysis of the risks have decreased the widespread skepticism surrounding them. The design of irreversible inhibitors is a challenge, particularly considering that in some cases their efficacy is due to complex and unexpected mechanisms of action. In this review the main advantages of irreversible inhibition are summarized, and the complexity of certain covalent modification mechanisms is highlighted with selected examples.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  covalent catalysis; efficiency; irreversible inhibition; selectivity; toxicity

Mesh:

Substances:

Year:  2015        PMID: 26593241     DOI: 10.1002/cmdc.201500469

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  13 in total

1.  A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Bioconjug Chem       Date:  2019-04-01       Impact factor: 4.774

Review 2.  The Taxonomy of Covalent Inhibitors.

Authors:  Alfred Tuley; Walter Fast
Journal:  Biochemistry       Date:  2018-04-30       Impact factor: 3.162

3.  Using Protein-Confined Proximity To Determine Chemical Reactivity.

Authors:  Tomonori Kobayashi; Christian Hoppmann; Bing Yang; Lei Wang
Journal:  J Am Chem Soc       Date:  2016-11-04       Impact factor: 15.419

4.  Electrophilic Helical Peptides That Bond Covalently, Irreversibly, and Selectively in a Protein-Protein Interaction Site.

Authors:  Aline Dantas de Araujo; Junxian Lim; Andrew C Good; Renato T Skerlj; David P Fairlie
Journal:  ACS Med Chem Lett       Date:  2016-11-15       Impact factor: 4.345

Review 5.  Redox Regulation of Soluble Epoxide Hydrolase-Implications for Cardiovascular Health and Disease.

Authors:  Rebecca Charles; Philip Eaton
Journal:  Cells       Date:  2022-06-15       Impact factor: 7.666

6.  Small molecule inhibitors of anthrax edema factor.

Authors:  Guan-Sheng Jiao; Seongjin Kim; Mahtab Moayeri; April Thai; Lynne Cregar-Hernandez; Linda McKasson; Sean O'Malley; Stephen H Leppla; Alan T Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-11-24       Impact factor: 2.823

7.  Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2.

Authors:  Natalia V Ortiz Zacarías; Kirti K Chahal; Tereza Šimková; Cas van der Horst; Yi Zheng; Asuka Inoue; Emy Theunissen; Lloyd Mallee; Daan van der Es; Julien Louvel; Adriaan P IJzerman; Tracy M Handel; Irina Kufareva; Laura H Heitman
Journal:  J Med Chem       Date:  2021-02-18       Impact factor: 7.446

8.  Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG Iα (Protein Kinase G Iα).

Authors:  Joseph R Burgoyne; Oleksandra Prysyazhna; Daniel A Richards; Philip Eaton
Journal:  Hypertension       Date:  2017-07-17       Impact factor: 10.190

Review 9.  The design and development of covalent protein-protein interaction inhibitors for cancer treatment.

Authors:  Sha-Sha Cheng; Guan-Jun Yang; Wanhe Wang; Chung-Hang Leung; Dik-Lung Ma
Journal:  J Hematol Oncol       Date:  2020-03-30       Impact factor: 17.388

10.  The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K.

Authors:  Elma Mons; Ineke D C Jansen; Jure Loboda; Bjorn R van Doodewaerd; Jill Hermans; Martijn Verdoes; Constant A A van Boeckel; Peter A van Veelen; Boris Turk; Dusan Turk; Huib Ovaa
Journal:  J Am Chem Soc       Date:  2019-02-14       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.